Actionable news
All posts from Actionable news
Actionable news in AEZS: AEterna Zentaris Inc.,

AEterna Zentaris: 1405 Du Parc-Technologique Blvd

The following excerpt is from the company's SEC filing.

Québec (Québec) Canada G1P 4P5 T 418-652-8525

Press Release

For immediate release

Aeterna Zentaris Reports Third Quarter Financial and Operating Results

Strong fundamentals; dilution from Series B Warrants substantially ended

All amounts are in US Dollars

Third quarter key developments


promotional activities show early promise


year-over-year new-prescription growth continues ahead of the market in the Company's territories

Zoptrex™ (zoptarelin doxorubicin) receives DSMB recommendation to continue Zo ptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data (after quarter end)

Zoptrex™ meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration- and Taxane-Resistant Prostate Cancer

Optimized Erk-Inhibitor Compound Selected for Further Development

Company announces restructuring of Financial Team and closing of Quebec City office (after quarter end)

Series B Share Purchase Warrants substantially eliminated (after quarter end)

- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported financial and operating results as at and for the third quarter ended September 30, 2015.

Commenting on third quarter results and the Company’s prospects, David A. Dodd, Chairman, President and Chief Executive Officer of the Company, stated, “Despite our continued progress in transforming the Company, the price of our common shares remained under intense pressure during the third quarter as a result of the exercise of Series B Common Share Purchase Warrants (“Series B Warrants”). At the beginning of the quarter, 26,812,308 Series B Warrants were outstanding. We finished the quarter with 6,880,170. As a result of the agreements we reached with the major holders of the Series B Warrants on November 1, only approximately 0.8 million Series B Warrants will remain outstanding, representing approximately 2.7% of the number originally issued. While the dilution caused by the Series B Warrants is substantially ended, we find it necessary to ask our fellow shareholders to approve another share consolidation. We believe that a share consolidation will permit our common shares to remain listed on The Nasdaq Capital Market, which will permit us to raise capital again on reasonable terms, further supporting our focus on developing a profitable, growth-oriented pharmaceutical business.”

Commenting on the Company's lead oncology compound, Mr. Dodd stated, "Our confidence in the commercial potential of Zoptrex™, which is the brand name we selected for zoptarelin doxorubicin, was enhanced by the announcement during the third quarter of the results of an investigator sponsored Phase 2 clinical study of Zoptrex™ in men with in castration- and taxane-resistant prostate cancer. Zoptrex™ achieved its primary endpoint and demonstrated good tolerability during this early-stage study. The primary endpoint was Clinical Benefit, defined as remaining progression-free by RECIST and Prostate Specific Antigen after treatment for 12+ weeks. Shortly after quarter end, we received very encouraging news regarding Zoptrex™ when, following a comprehensive review of the final interim efficacy and safety data, the DSMB recommended that we continue the ZoptEC Phase 3 clinical study to its conclusion. We look forward to the successful completion of the clinical development of Zoptrex

for our initial indication over the next year."

Continuing with his commentary, Mr. Dodd stated, "During the third quarter, we made progress promoting Saizen

, a leading product in the $1.6 billion US market for the treatment of growth hormone deficiency in children and adults. Our recently commenced promotional efforts for Saizen

show promise and support our belief that detailing this product will contribute to our commercial success. In addition, year-over-year new prescription growth for EstroGel

in our territories increased significantly, compared to its market which...